ATE462433T1 - Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums - Google Patents
Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstumsInfo
- Publication number
- ATE462433T1 ATE462433T1 AT03078539T AT03078539T ATE462433T1 AT E462433 T1 ATE462433 T1 AT E462433T1 AT 03078539 T AT03078539 T AT 03078539T AT 03078539 T AT03078539 T AT 03078539T AT E462433 T1 ATE462433 T1 AT E462433T1
- Authority
- AT
- Austria
- Prior art keywords
- agents
- ppargamma
- methods
- pharmaceutical compositions
- tumor growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76655396A | 1996-12-11 | 1996-12-11 | |
US08/923,346 US6552055B2 (en) | 1996-12-11 | 1997-09-04 | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE462433T1 true ATE462433T1 (de) | 2010-04-15 |
Family
ID=27117766
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03078539T ATE462433T1 (de) | 1996-12-11 | 1997-12-11 | Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums |
AT97952407T ATE253903T1 (de) | 1996-12-11 | 1997-12-11 | Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97952407T ATE253903T1 (de) | 1996-12-11 | 1997-12-11 | Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor |
Country Status (8)
Country | Link |
---|---|
US (1) | US7635708B2 (de) |
EP (2) | EP0948324B1 (de) |
JP (2) | JP4549443B2 (de) |
AT (2) | ATE462433T1 (de) |
AU (1) | AU5601898A (de) |
CA (1) | CA2274756C (de) |
DE (2) | DE69726182T2 (de) |
WO (1) | WO1998025598A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1005344A4 (de) * | 1996-12-31 | 2003-03-19 | Salk Inst For Biological Studi | Behandlung von liposarcomas mit einer kombination aus thiazolidinedions und selektiven retinoid-x-rezeptor agonisten |
US5814647A (en) | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
FR2773075B1 (fr) | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
WO1999048529A1 (en) * | 1998-03-20 | 1999-09-30 | Warner-Lambert Company | Retinoid-glitazone combinations |
WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
GB9908647D0 (en) * | 1999-04-15 | 1999-06-09 | Smithkline Beecham Plc | Novel compounds |
GB9917405D0 (en) * | 1999-07-23 | 1999-09-22 | Univ Dundee | Methods of treatment and drug screening methods |
US6723506B2 (en) | 2000-01-20 | 2004-04-20 | Brigham And Women's Hospital | Method of identifying PAX8-PPAR gamma-nucleic acid molecules |
WO2002013864A1 (fr) * | 2000-08-16 | 2002-02-21 | Sankyo Company, Limited | Preparation medicinale de prevention et traitement du cancer |
CA2419567A1 (en) | 2000-09-01 | 2002-03-07 | George Vande Woude | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
US7323481B2 (en) | 2001-04-06 | 2008-01-29 | Hoffmann-La Roche Inc. | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth |
US6756399B2 (en) | 2001-06-29 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents |
US20040197834A1 (en) * | 2001-07-20 | 2004-10-07 | Francois Gervais | Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors |
WO2003032988A1 (fr) * | 2001-10-17 | 2003-04-24 | Sankyo Company, Limited | Composition pharmaceutique |
JP5249484B2 (ja) * | 2001-12-11 | 2013-07-31 | 第一三共株式会社 | 医薬組成物 |
AU2002354460A1 (en) * | 2001-12-11 | 2003-07-09 | Sankyo Company, Limited | Medicinal composition |
WO2003082865A1 (fr) * | 2002-04-01 | 2003-10-09 | Sankyo Company, Limited | Composition médicinale antitumorale |
WO2004000356A1 (ja) * | 2002-06-25 | 2003-12-31 | Sankyo Company, Limited | 利尿剤及びペルオキシソーム増殖因子活性化受容体(PPAR)γ活性化剤を含有する医薬組成物 |
JP2004083574A (ja) * | 2002-06-25 | 2004-03-18 | Sankyo Co Ltd | 利尿剤及びペルオキシソーム増殖因子活性化受容体(PPAR)γ活性化剤を含有する医薬組成物 |
HU0301358D0 (en) | 2003-05-14 | 2003-07-28 | Debreceni Egyetem | Novel use of ppargamma agonists |
WO2005003100A2 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
JP4556511B2 (ja) * | 2004-06-25 | 2010-10-06 | ソニー株式会社 | 15d−PGJ2、及び、15d−PGJ2を用いた方法 |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
JP2006232754A (ja) * | 2005-02-25 | 2006-09-07 | Gi Biopolis:Kk | 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤 |
AU2006223000B2 (en) * | 2005-03-14 | 2011-06-30 | Center For Molecular Medicine And Immunology | Methods of treating cancer using PPAR-gamma antagonists |
US20080194646A1 (en) | 2005-03-21 | 2008-08-14 | Sanders Martin E | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders |
SI1937244T1 (sl) | 2005-09-30 | 2018-12-31 | Io Therapeutics, Llc | Zdravljenje raka s specifičnimi RXR agonisti |
CN101336113B (zh) | 2005-11-28 | 2015-07-29 | 千寿制药株式会社 | 包括ppar激动剂的药物 |
ES2393424T3 (es) | 2007-05-21 | 2012-12-21 | Senju Pharmaceutical Co., Ltd. | Agente farmacéutico que contiene un agonista de PPAR-delta |
WO2010070379A1 (en) * | 2008-12-17 | 2010-06-24 | Centre National De La Recherche Scientifique | Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer |
AU2012275190B2 (en) | 2011-06-29 | 2016-05-19 | The Penn State Research Foundation | Compositions, methods and kits for treating leukemia |
MX352727B (es) | 2011-12-13 | 2017-12-06 | Dartmouth College | Tratamiento de trastorno autoinmune al usar agonistas de rxr. |
JP5987175B2 (ja) * | 2012-07-02 | 2016-09-07 | 学校法人福岡大学 | 乳癌,胃癌及び卵巣癌等に対する制癌剤 |
CA2890086C (en) | 2012-11-05 | 2022-05-31 | Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) | Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse |
CN107073079A (zh) * | 2014-09-08 | 2017-08-18 | 达纳-法伯癌症研究所公司 | 包括给予PPAR‑γ激动剂的治疗癌症的方法 |
WO2017075612A1 (en) * | 2015-10-31 | 2017-05-04 | Io Therapeutics, Inc. | Treatment of cancer with combinations of rxr agonists and thyroid hormones |
PL3368080T3 (pl) | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
US10960013B2 (en) * | 2016-03-04 | 2021-03-30 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
KR20230164204A (ko) | 2016-03-10 | 2023-12-01 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
EP3426303B1 (de) | 2016-03-10 | 2022-06-15 | IO Therapeutics, Inc. | Behandlung von muskelerkrankungen mit kombinationen von rxr-agonisten und schilddrüsenhormonen |
CA3076373A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | Treatment of disease with esters of selective rxr agonists |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
CA3191858A1 (en) * | 2020-09-08 | 2022-03-17 | National University Corporation Ehime University | Fluorescent dye and method for detecting tumor cells |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
ATE307795T1 (de) * | 1992-04-22 | 2005-11-15 | Ligand Pharm Inc | Verbindungen mit retinoid x rezeptorselektivität |
US5552271A (en) * | 1992-06-16 | 1996-09-03 | La Jolla Cancer Research Foundation | RXR homodimer formation |
US5466861A (en) * | 1992-11-25 | 1995-11-14 | Sri International | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors |
AU668818B2 (en) * | 1993-04-07 | 1996-05-16 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
EP0724636A1 (de) | 1993-10-22 | 1996-08-07 | Ligand Pharmaceuticals, Inc. | Menschlichen "peroxisomen proliferator" aktivierte rezeptor |
WO1995018533A1 (en) | 1994-01-04 | 1995-07-13 | The Trustees Of The University Of Pennsylvania | Methods and compounds affecting adipocyte differentiation and obesity |
US5514821A (en) * | 1994-05-27 | 1996-05-07 | Ligand Pharmaceuticals Incorporated | Ring-labeled retinoids and intermediates, and methods for their synthesis and use |
US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
JPH10502454A (ja) | 1994-07-01 | 1998-03-03 | リガンド・ファーマシューティカルズ・インコーポレーテッド | Nuc阻害剤のスクリーニング |
JPH10502256A (ja) | 1994-07-01 | 1998-03-03 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 哺乳動物のペルオキシソーム増殖物質活性化受容体およびその使用 |
JP2848964B2 (ja) | 1994-08-10 | 1999-01-20 | エフ・ホフマン−ラ ロシュ アーゲー | レチノイン酸x受容体リガンド |
US6022897A (en) * | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
EP0824583A1 (de) * | 1995-05-04 | 1998-02-25 | City Of Hope | 12-lipoxygenase aus menschlichen leukozyten und ihre wirkung in der krankheitszuständen-pathogenese |
US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
TW474809B (en) * | 1995-07-03 | 2002-02-01 | Sankyo Co | A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers |
PT859608E (pt) * | 1995-09-18 | 2004-06-30 | Ligand Pharm Inc | Tratamento de niddm com agonistas de rxr |
AU1074897A (en) * | 1995-11-08 | 1997-05-29 | University Of South Florida | Guinea pig model for leiomyomas and atherosclerosis |
US5814647A (en) * | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
-
1997
- 1997-12-11 DE DE69726182T patent/DE69726182T2/de not_active Expired - Lifetime
- 1997-12-11 AU AU56018/98A patent/AU5601898A/en not_active Abandoned
- 1997-12-11 AT AT03078539T patent/ATE462433T1/de not_active IP Right Cessation
- 1997-12-11 EP EP97952407A patent/EP0948324B1/de not_active Expired - Lifetime
- 1997-12-11 EP EP03078539A patent/EP1410799B1/de not_active Expired - Lifetime
- 1997-12-11 JP JP52700198A patent/JP4549443B2/ja not_active Expired - Fee Related
- 1997-12-11 CA CA002274756A patent/CA2274756C/en not_active Expired - Fee Related
- 1997-12-11 AT AT97952407T patent/ATE253903T1/de active
- 1997-12-11 DE DE69739828T patent/DE69739828D1/de not_active Expired - Lifetime
- 1997-12-11 WO PCT/US1997/022879 patent/WO1998025598A2/en active IP Right Grant
-
2002
- 2002-12-19 US US10/324,744 patent/US7635708B2/en not_active Expired - Fee Related
-
2008
- 2008-08-19 JP JP2008210954A patent/JP4550133B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69726182T2 (de) | 2004-08-12 |
JP2001510462A (ja) | 2001-07-31 |
EP1410799A1 (de) | 2004-04-21 |
JP4549443B2 (ja) | 2010-09-22 |
JP2009063566A (ja) | 2009-03-26 |
WO1998025598A2 (en) | 1998-06-18 |
EP0948324A2 (de) | 1999-10-13 |
WO1998025598A3 (en) | 1998-07-30 |
EP1410799B1 (de) | 2010-03-31 |
CA2274756A1 (en) | 1998-06-18 |
JP4550133B2 (ja) | 2010-09-22 |
CA2274756C (en) | 2007-03-13 |
ATE253903T1 (de) | 2003-11-15 |
EP0948324B1 (de) | 2003-11-12 |
DE69739828D1 (de) | 2010-05-12 |
AU5601898A (en) | 1998-07-03 |
US20030144330A1 (en) | 2003-07-31 |
US7635708B2 (en) | 2009-12-22 |
DE69726182D1 (de) | 2003-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69739828D1 (de) | Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums | |
ES2153337T1 (es) | Inhibidores de raf-quinasa. | |
DE59903921D1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
MXPA02005196A (es) | Inhibidores de deacetilasa de histona. | |
DE3683374D1 (de) | Mikrobielle zusammensetzungen und verfahren zur behandlung vom boden. | |
DE3675792D1 (de) | Vorrichtung zur behandlung von bohrloechern. | |
TR199802385T2 (xx) | TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler. | |
DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
NO985652L (no) | Anvendelse av naaladaseinhibitorer ved behandling av kreft | |
AR024138A1 (es) | Inhibidores de la proliferacion celular | |
ATE418999T1 (de) | Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung | |
DE3779930D1 (de) | Zusammensetzungen zur oberflaechenbehandlung, polymere dafuer und verfahren zur oberflaechenbehandlung. | |
ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
NO20010956L (no) | Modulering av hukommelseseffektor T-celler samt midler for dette | |
IS1407B6 (is) | Útbúnaður til að nema burtu yfirborð af vöðvavef dýra, einkum fiskflaka | |
NO20003848D0 (no) | FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien | |
DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
DE69932342D1 (de) | Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums | |
DE60224778D1 (de) | Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen | |
BR9815617A (pt) | Compostos substituìdos de 11-fenil-dibenzazepina, composição farmacêutica baseada nos referidos compostos, e métodos para inibir a proliferação de células de mamìferos e para tratamento ou prevenção de desordem causada por proliferação anormal de células | |
HUP9903685A2 (hu) | Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATA344985A (de) | Vorrichtung zur behandlung von gewaesserablagerungen | |
WO2003028537A3 (en) | Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer | |
WO2003007800A3 (en) | Methods for diagnosing and treating diseases and conditions of the digestive system and cancer | |
PT1169054E (pt) | Produtos e metodos para tratar doencas relacionadas com ptp lar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |